Don't miss an issue! Renew/subscribe for FREE today.

St. Renatus, LLC Completes All Planned FDA Clinical Studies of Nasal Anesthetic for Dentistry

Posted on Friday, February 21, 2014


FORT COLLINS, Colo. – February 21, 2014 – St. Renatus, LLC announced today it has completed Phase 3 clinical studies and is preparing its analysis for submission to the U.S. Food and Drug Administration (FDA). The studies tested the safety and efficacy of St. Renatus’ nasal mist technology in adult and pediatric subjects. 

St. Renatus conducted its pediatric Phase 3 studies at multiple sites around the country where pediatric patients ranging in age from 3 to 17 years were administered the nasal mist instead of needle-based dental anesthesia.

“We are very pleased with how the nasal mist has performed in our Phase 3 studies. Completing Phase 3 is a critical milestone for a new drug; it is rare for investigative new drugs to get this far in the process,” said Steve Merrick, Chief Executive Officer for St. Renatus, LLC. “The next big milestone islocking the study data and completing the statistical analysis for these Phase 3 studies. We are looking forward to completing the analysis and are hopefulit will depict a positive, safety and efficacy profile of our drug, so that we can continue toward FDA submission, review and final approval.”

St. Renatus’ nasal mist technology was required to complete three phases of clinical human studies by the FDA. St. Renatus completed Phase 1 clinical human studies in 2007, Phase 2 studies were conducted from 2008 through 2011 and the company completed an End of Phase 2 Meeting with the FDA in March 2011. Phase 3 studies began early in 2013 and were completed in the fourth quarter of 2013, and are the last phase of clinical studies required by the FDA prior to submission for approval. Preliminary data is being analyzed by St. Renatus and its team of qualified consultants. The statistical results will be the foundation of the New Drug Application (NDA), which the company plans to submit to the FDA for review in 2014.

About St. Renatus

St. Renatus, LLC was founded to develop a revolutionary innovation – the world's first dental anesthetic administered through the nasal cavity designed for use in procedures involving most of the upper teeth, with a goal of gaining FDA approval to commercialize and distribute. St. Renatus’ name comes from the patron saint of anesthesia and has Latin roots meaning new beginning.

St. Renatus believes the benefits of its product will provide a better experience for doctors and qualifying patients. These benefits could include an accurate and sophisticated method to anesthetize the upper teeth topically, without the use of a dental needle injection.

For more information, please visit or call 970.282.0156.

Recent Headlines

© 2024 BroadcastMed LLC | Privacy Policy